Abstract 350P
Background
The diagnosis and treatment of breast cancer involves changes in personal, family, social, professional and sexual relationships. In this study we assessed sexual satisfaction in patients with early breast cancer using the validated SEXSAT-Q scale.
Methods
We used the SEXSAT-Q quality of life questionnaire in 60 patients diagnosed with early breast cancer at our centre. Six dimensions were studied: 1. Loss of sexual desire. 2. Alteration of body image. 3. Psychological coping. 4. Discomfort during sexual intercourse. 5. Satisfaction during sexual intercourse. 6. Satisfaction with breast reconstruction. Data were collected in Medical Oncology Department during March 2023.
Results
A sample of 60 patients was selected, aged 26-72 years old, with a median age of 52 years, who had undergone breast cancer surgery, 73.33% by conservative surgery. 20% were premenopausal, 10% were perimenopausal and 70% were menopausal. 35% were being treated with chemotherapy, 56.67% with hormonoterapy and 8.33% with anti-HER2. 78.33% had a stable partner and did not use contraception. 30% of patients were quite or very sad and depressed since starting treatment. 50% of patients believe that the treatment has worsened their body image. 75% reported that during treatment their sexual relations were not satisfactory. 61.67% believe that their sexual desire has decreased and 45% admit having more problems reaching orgasm since diagnosis.
Conclusions
Women with curable breast cancer it is important to know the impact of diagnosis and treatment on the sexual sphere. The SEXSAT-Q questionnaire is a validated scale capable of measuring the sexual satisfaction of our patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M.L. Garrido Onecha.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
403P - Breast cancer specific survival (BCSS) in HR+/HER2- metastatic breast cancer (mBC) from 2010 to 2019
Presenter: Adam Brufsky
Session: Poster session 03
404P - A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer
Presenter: Jiayu Wang
Session: Poster session 03
405P - E7389-LF as a first-line (1L) chemotherapy for patients (pts) with metastatic/advanced HER2-negative breast cancer (HER2− BC): Results from a phase I study dose-expansion part
Presenter: Kan Yonemori
Session: Poster session 03
406P - Phase Ib safety and efficacy of nadunolimab/gemcitabine/carboplatin in mTNBC
Presenter: Sara Lopez-Tarruella Cobo
Session: Poster session 03
407P - Palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer patients: Interim results of the PERFORM study
Presenter: Julia C. Radosa
Session: Poster session 03
408P - Proxalutamide plus endocrine therapy as a combination therapy in women with HR+/HER2-/AR+ metastatic breast cancer: A phase I study
Presenter: Huiping Li
Session: Poster session 03
410P - Patients treated with pertuzumab followed by T-DM1 for breast cancer in France from 2014 to 2021: A survival analysis of 10,408 patients from the French National Hospital discharge summary database (PMSI)
Presenter: Josephine Lemaitre
Session: Poster session 03
411P - Therapy management and safety of 1st-line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))
Presenter: Frederik Marmé
Session: Poster session 03
412P - Sacituzumab govitecan versus chemotherapy for metastatic breast cancer: A meta-analysis on safety outcomes
Presenter: Alessandro Rizzo
Session: Poster session 03